Our musculoskeletal system is essential for movement and to give our body structure. The system is made up of bones (skeleton) and soft connective tissues (muscles, tendons, cartilage and ligaments )that enable the skeleton to move. These tissues contain cells that work together to help the tissue function and grow normally. Our musculoskeletal system changes continuously from infancy to adulthood, with each tissue type changing in both size and shape, and they become less effective at repairing themselves when injured. Our ...

GO TO STUDY

There are Four treatment groups using a 1:1:1:1 ratio, who will receive a study treatment for 24 weeks. For intervention group amlitelimab + GF, they will have amlitelimab 500mg loading dose followed by a 250mg dose once every four weeks + gluten free products for the full 24 weeks. Intervention group placebo + Gluten free, will have matching placebo and gluten free products for the full 24 weeks. The amlitelimab + SIGE (simulated inadvertent gluten exposure) group, will have amlitelimab ...

GO TO STUDY

This is a Phase 2a PoC, treat-through, multicenter, randomized, open label, platform study in CD subjects. This platform study is designed as a series of "intervention sets" that will run in parallel but may not be initiated at the same time. Each intervention set will include 1 or more treatment arms depending on the objective of the intervention set. In addition, 1 treatment arm will be incorporated as a common comparator arm across other intervention sets. Additional "intervention sets" and/or ...

GO TO STUDY

Bowel cancer is one of the leading causes of cancer-related deaths worldwide. In the early stages of the disease, many patients can be cured with surgery. However, in the later stages, bowel cancer can return or progress even after surgery and chemotherapy. One potential way of preventing relapse is by making the patient’s immune system better at detecting and destroying any cancer cells that might remain after treatment. T cells are a type of white blood cell that play a ...

GO TO STUDY

All patients who are diagnosed with womb, bowel, or ovary cancer are recommended to have genetic-testing to see if their cancer was related to an inherited gene alteration. Identifying carriers of alterations allows novel personalised cancer treatments, prevention of second cancers, and testing of family members for cancer screening and prevention. Genetic testing requires pre-test counselling to ensure patients are informed about the impact of having a genetic test and managing the result. This ‘genetic-counselling’ has traditionally been provided by genetics ...

GO TO STUDY

This is a global, multicenter, randomized, open-label, Phase 3 study designed to compare the efficacy and safety of I-DXd with the TPC in subjects with relapsed SCLC. Eligible subjects will have received one prior line of platinum-based therapy and at least 75% of whom will have received prior treatment with anti-programmed death-(ligand) 1 (PD-[L]1) antibody. Subjects must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤1. This study is designed to randomize at least 468 subjects in a ...

GO TO STUDY

The Monoclonal Antibody Medications in inflammatory Arthritis (MAMA) trial is designed to address the significant uncertainty and resulting variation in practice surrounding the effects of continuing or stopping biologics during pregnancy. There are no randomised trials which compare stopping or continuing biologics in head-to-head studies in an Autoimmune Inflammatory Arthritis (AIA) population. This study aims to fill the gap in evidence and enable evaluation of arthritis disease activity,pregnancy,and infant outcomes in women randomly allocated to continuing their biologic medication throughout ...

GO TO STUDY

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies. Module 1 will initially focus on monotherapy in participants with locally advanced or metastatic solid malignancies and include dose escalation cohorts (Part A) and dose optimization cohorts (Part B) (Appendix A). In Parts A and B of Module 1, a SRC, consisting of study investigators and sponsor medical ...

GO TO STUDY

Radiotherapy to the chest is widely used in the treatment of lung cancer. Its use in stage IV non-small cell lung cancer (NSCLC) has evolved worldwide based on local experience, as doctors attempt to ease symptoms, maintain/improve quality of life, and prolong survival, while minimising side effects. Current palliative thoracic radiotherapy practice is still based on dose fractionations that were studied in the 1990s. However, the past 30 years have seen profound changes in the management of advanced lung cancer, ...

GO TO STUDY

Acute myeloid leukaemia (AML), is an ‘aggressive’ blood cancer with only around 20% of affected adults surviving at 5 years. AML often presents as a medical emergency and treatment is intensive. After the initial course of urgent anticancer therapy, people with AML receive repeated intensive courses of chemotherapy aimed at cure, that may include ‘haemopoietic’ (blood) stem cell transplantation. They need to remain in hospital during courses of treatment, often in isolation, due to risk of infection, with short periods ...

GO TO STUDY